A9.6 Identification of New Potential Therapeutic Targets for the Treatment of Rheumatoid Arthritis: ENTPD1 (CD39) and 5NTE1 (CD73)

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2013-203223.6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets

Immunological Reviews
AllergyImmunology
2017English

Sphingosine-1-Phosphate and Rheumatoid Arthritis: Pathological Implications and Potential Therapeutic Targets

2013English

Baricitinib: A New Oral Treatment for Rheumatoid Arthritis

Prescriber
Pharmacology
2017English

Profile of Sarilumab and Its Potential in the Treatment of Rheumatoid Arthritis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Method for Assessing Therapeutic Potential of Anti-Inflammatory Antirheumatic Drugs in Rheumatoid Arthritis

BMJ
1973English

Inhibition of Hexokinases Holds Potential as Treatment Strategy for Rheumatoid Arthritis

Arthritis Research & Therapy
2019English

Sarilumab for the Treatment of Rheumatoid Arthritis

Immunotherapy
OncologyAllergyImmunology
2016English

The Treatment of Rheumatoid Arthritis.

JAMA - Journal of the American Medical Association
Medicine
1929English

Shared Immunological Targets in the Lungs and Joints of Patients With Rheumatoid Arthritis: Identification and Validation

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy